Vivos Therapeutics 

Yahoo Finance • 20 days ago

Vivos Therapeutics Inc Full Year Sales Increase

(RTTNews) - Vivos Therapeutics Inc (VVOS) released Loss for full year of -$21.17 million The company's earnings came in at -$21.17 million, or -$2.07 per share. This compares with -$11.14 million, or -$2.22 per share, last year. The com... Full story

Yahoo Finance • 21 days ago

Vivos Therapeutics Reports Full Year 2025 Financial Results

Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo.,... Full story

Yahoo Finance • 5 months ago

Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST

LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic... Full story

Yahoo Finance • 6 months ago

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review result... Full story

Yahoo Finance • 6 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic... Full story

Yahoo Finance • 7 months ago

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.(“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effe... Full story

Yahoo Finance • 7 months ago

SJM Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of J.M. Smucker Co. (Symbol: SJM) crossed above their 200 day moving average of $116.85, changing hands as high as $125.42 per share. J.M. Smucker Co. shares are currently trading up about 8.1% on the day. T... Full story

Yahoo Finance • 8 months ago

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.(“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effe... Full story

Yahoo Finance • 9 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call t... Full story

Yahoo Finance • 9 months ago

Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, t... Full story

Yahoo Finance • 10 months ago

Vivos sleep apnea device gains Medicare coverage approval

LITTLETON, Colo. - Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced Tuesday that its VidaSleep oral appliance has received approval from the Centers for Medicare & Medicaid Services (CMS) for the treatment of mild to moderate obstructive s... Full story

Yahoo Finance • 11 months ago

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos’ business model pivot to target high... Full story

Yahoo Finance • 12 months ago

Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Manag... Full story

Yahoo Finance • last year

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- V... Full story

Yahoo Finance • last year

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effe... Full story

Yahoo Finance • 2 years ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effect... Full story

Yahoo Finance • 2 years ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expected to Add Potentially Significant Ne... Full story

Yahoo Finance • 2 years ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abno... Full story

Yahoo Finance • 3 years ago

Vivos Therapeutics Closes $4 Million Private Placement

LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abno... Full story

Yahoo Finance • 3 years ago

Vivos Therapeutics Announces Reverse Stock Split

LITTLETON, Colo., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate... Full story